Indian Journal of Gastroenterology

, Volume 33, Issue 1, pp 31–34 | Cite as

Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience

  • Ajit Sood
  • Vandana Midha
  • Suresh Sharma
  • Neena Sood
  • Manu Bansal
  • Amandeep Thara
  • Pankaj Khanna
Original Article

Abstract

Introduction

The role of infliximab in the treatment of acute severe ulcerative colitis is established. However, all the data available in the literature are from western countries. This is the first report on the use of infliximab in patients with severe steroid-refractory ulcerative colitis from India.

Methods

Retrospective analysis of 28 patients who had received infliximab therapy for induction of remission, with three doses of 5 mg/kg at 0, 2, and 6 weeks, was performed.

Results

Twenty-four (85.6 %) patients had shown a clinical response by week 8 and, hence, avoided urgent colectomy. In 2 years of follow up, 9/16 (56 %) patients had not required colectomy.

Conclusion

Infliximab averted colectomy in a proportion of patients with severe steroid-refractory ulcerative colitis.

Keywords

Biologicals Inflammatory bowel disease Rescue therapy 

References

  1. 1.
    Porro GB, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779–94.CrossRefGoogle Scholar
  2. 2.
    Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gasteroenterol. 2008;14:354–77.CrossRefGoogle Scholar
  3. 3.
    Knight DM, Trin H, Le J, et al. Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRefGoogle Scholar
  5. 5.
    Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT1 and ACT2 extension studies. Inflamm Bowel Dis. 2012;18:201–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Lichtiger S, Present D, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med. 1994;330:1841–5.CrossRefGoogle Scholar
  7. 7.
    Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependent and refractory ulcerative colitis. World J Gastroenterol. 2008;14:2544–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998–1002.PubMedCrossRefGoogle Scholar
  11. 11.
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83–8.PubMedCrossRefGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2013

Authors and Affiliations

  • Ajit Sood
    • 1
  • Vandana Midha
    • 1
  • Suresh Sharma
    • 1
  • Neena Sood
    • 1
  • Manu Bansal
    • 1
  • Amandeep Thara
    • 1
  • Pankaj Khanna
    • 1
  1. 1.Dayanand Medical CollegeLudhianaIndia

Personalised recommendations